CADL Oct 2024 10.000 call
| Previous Close | 1.3000 |
| Open | 1.3000 |
| Bid | 1.0500 |
| Ask | 2.0000 |
| Strike | 10.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 1.3000 - 1.3000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 120 |
ACCESSWIRECandel Therapeutics' (NASDAQ:CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
By Jeremy Golden, Benzinga By Jeremy Golden, Benzinga NEEDHAM, MA / ACCESSWIRE / June 14, 2024 /Candel Therapeutics, Inc. (NASDAQ:CADL) is helping pioneer the next generation of viral immunotherapy by leveraging a data-driven approach to create new ...
GlobeNewswireCandel Therapeutics to Join Russell 3000® Index
NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary
- ACCESSWIRE
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
By Jeremy Golden, Benzinga NEEDHAM, MA / ACCESSWIRE / June 3, 2024 / Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. (NASDAQ:CADL) reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline ...
